Eli Lilly Antibody Cuts Covid-19 Risk Up to 80% in Nursing Home Study

Source: Bloomberg

By Riley Griffin

Eli Lilly & Co.’s antibody therapy reduced nursing home residents’ risk of symptomatic Covid-19 by as much as 80% when used preventively in a study.

The infused treatment, cleared for use in high-risk Covid patients with mild-to-moderate disease who haven’t been hospitalized, also significantly reduced the risk of symptomatic disease in nursing home workers, according to a statement from Lilly on Thursday.

The U.S. is prioritizing Covid-19 vaccines from Moderna Inc.Pfizer Inc. and other manufacturers for elderly people and health-care workers. The results suggest that Lilly’s treatment, called bamlanivimab, may also play a role in the effort to keep nursing home patients and staff from developing severe, potentially lethal illness.

With more than 400,000 deaths since the outset of the pandemic, the U.S. is the world leader in Covid mortality. Nursing home residents represent about a quarter of those fatalities, according to data from the Centers for Medicare & Medicaid Services.

Read further

Categories: Health

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.